OCU410
Asset
Delivers the RORA gene to retinal cells to regulate lipid metabolism, inflammation, and oxidative stress.
- Stage
- Phase 3
- Modality
- Gene therapy
- Target
- Not known
- 2
- Indications
- 2
- Trials
- 1
- Developer
2 trials are still running. Trial NCT06018558 updated in its registry on Nov 10, 2026. clinicaltrials.gov
Indications
2Dry age-related macular degeneration
Phase 3, Recruiting, NCT07770828, clinicaltrials.gov, Oct 31, 2026
Geographic atrophy
Phase 1, Active not recruiting, NCT06018558, clinicaltrials.gov, Oct 30, 2026
In the full profile
- Owner and partners1
- Trials2
- Competitors6
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.